GlassScriptPhysician profile
Emma Saber
NPI 1174122873
$2,956.51
in general payments reported to CMS, 2019-2025
26 companies · $1,160 in 2025
The $1,160 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $410 · 2022: $625 · 2023: $318 · 2024: $444 · 2025: $1,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,921.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,921.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endogastric Solutions, INC | $431.55 | 2021-2022 | |
| Amgen INC. | $364.55 | 2025 | Krystexxa, Otezla, Prolia |
| Intuitive Surgical, INC. | $278.98 | 2021 | |
| Davol INC. | $267.16 | 2022-2024 | Phasix Mesh |
| Ucb, INC. | $209.29 | 2025 | Bimzelx |
| Abbvie INC. | $201.14 | 2025 | |
| Lucid Diagnostics INC. | $184.18 | 2023-2024 | |
| Ethicon US, LLC | $183.86 | 2022-2023 | Linx Reflux Management System |
| Medtronic, INC. | $127.66 | 2022-2023 | Endoflip |
| Novartis Pharmaceuticals Corporation | $95.91 | 2025 | |
| Cvrx, INC. | $95.27 | 2022 | |
| Smith+Nephew, INC. | $90.03 | 2024-2025 | Grafix Pl, Stravix |
| Enterra Medical, INC. | $80.39 | 2023-2025 | |
| Janssen Biotech, INC. | $67.32 | 2025 | Tremfya |
| Novo Nordisk INC | $65.28 | 2022-2025 | Wegovy |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $29.02 | 2025 | Renflexis, Hadlima |
| Recordati_rare_diseases_inc. | $26.67 | 2024 | Isturisa, Signifor Lar |
| Solventum Corporation | $23.12 | 2024 | Prevena, V.A.C. Veraflo |
| Lilly USA, LLC | $22.25 | 2025 | Zepbound |
| Astrazeneca Pharmaceuticals LP | $20.22 | 2025 | Saphnelo |
| Takeda Pharmaceuticals U.S.A., INC. | $19.43 | 2021 | |
| Ani Pharmaceuticals, INC. | $19.39 | 2025 | Purified Cortrophin Gel |
| Sandoz INC. | $16.34 | 2025 | Jubbonti |
| Teleflex LLC | $13.92 | 2023 | Weck |
| Ambu INC. | $12.40 | 2022 | |
| Polynovo North America LLC | $11.18 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emma Saber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.